3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Unknown
1
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
13
Lung Neoplasms
2
Esophageal Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Sjogren's Syndrome
1
Scleroderma, Systemic
1
Retinoblastoma
1
Resectable Stage II-III Non-Small Cell Lung Cancer (NSCLC)
1
Resectable Non-small Cell Lung Cancer
1
Resectable Lung Non-Small Cell Carcinoma
1
Recurrence
1
Psoriasis
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Multiple Sclerosis
1
Lupus Erythematosus, Systemic
1
Inflammatory Bowel Diseases
1
Hematologic Neoplasms
1
Dermatomyositis
1
Crohn Disease
1
Colitis, Ulcerative
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Bronchogenic
1
Bronchial Neoplasms
1
Autoimmune Diseases
1
Arthritis, Rheumatoid
1
Arthritis, Psoriatic
1
Advanced Non-small Cell Lung Cancer
1
Interventions
pembrolizumab
47
Specimen Handling
29
Magnetic Resonance Spectroscopy
25
Biopsy
25
Radiosurgery
17
Gemcitabine
17
Nivolumab
15
Paclitaxel
14
Cyclophosphamide
13
Cisplatin
13
Carboplatin
13
Bevacizumab
12
Drug Therapy
11
Taxes
10
Radiotherapy
10
Oxaliplatin
10
Leucovorin
10
Irinotecan
10
Fluorouracil
10
Capecitabine
10
trastuzumab deruxtecan
8
fludarabine
8
Pemetrexed
8
Doxorubicin
8
Cetuximab
8
cemiplimab
7
abemaciclib
7
Trastuzumab
7
Fulvestrant
7
Docetaxel
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Neoplasm Metastasis
×
Platinum Compounds
×
Clear all
NCT06216301
2025-12-17
LUNAR-2
NovoCure Ltd.
Phase 3
Recruiting
734 enrolled